The goal is to provide the highest quality therapeutic pharmaceutical products that resolve issues for the healthcare industry, including patients, clinics, institutions, and physicians. This is accomplished by adhering to extensive and continuous quality control and assurance programs, focusing on and in strict compliance with Current Good Manufacturing Processes (CGMP) and U.S. Pharmacopeia Guidelines (USP) and regulations. In addition, our firm complies with all applicable federal, state, and local statutes and regulations in effect and maintains a high level of efficacy, consistency, and quality in each of our medications.
The firm was established in 2015, and has developed and maintained a successful reputation and history, constantly committed to exceeding current manufacturing standards. Our cutting edge technology is evidenced by our quality assurance program, and our commitment to precision in personalized and commercially available medication. The firm has embraced a philosophy of developing medications based on the principals of high patient demand and solving for limited availability of products.
Depression affects 80-90 million people in the U.S. and 280 million people worldwide, with over 25-30% of these cases involving Major Depressive Disorder (MDD) or Treatment Resident Depression (TRD). As a result of the pandemic, these numbers have dramatically increased. Hair loss affects approximately 50 million men and 30 million women in the U.S.. Neuropathic pain and chronic pain affect between 15-20% of the U.S. population. Substance addiction affects over 10% of adults at some point in their lives and has also increased as a result of the pandemic. Female sexual dysfunction affects over 30-40% of women.
Other revolutionary medications in research and development consist enhancing treatments for Postpartum Depression, Post Traumatic Stress Disorder, and Bipolar Disorder.